About: HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy     Goto   Sponge   Distinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Studovali jsme efekty IL-12 produkujících buněčných vakcín na cytotoxický a proliferační potenciál CD45+ buněk infiltrujících nádory (TIL) na myším modelu pro HPV16 asociované nádory po chemoterapii pomocí CBM-4A (derivát ifosfamidu). Účinkem chemoterapie poklesly populace inflitrujících CD4+ and CD8+ TIL, zvýšily Gr-1+/CD11b+ TIL a nebyly žádné změny v infiltraci CD4+/CD25+ Treg TIL. Byl pozorován pokles v cytotoxickém a proliferačním potenciálu CD45+ TIL. Následná imunoterapie geneticky modifikovanými nádorovými buňkami TC-1 produkujícími IL-12 zvýšila množství CD8+ a CD4+ buněk infiltrujících nádor, snížila množství Gr-1+/CD11b+ buněk a zvýšila proliferační a cytolytický potenciál CD45+ TIL. Tyto výsledky ukazují, že IL-12 produkující buněčné vakcíny jsou schopny restaurovat cytolytický potenciál TIL a inhibovat jejich imunosupresivní účinky. (cs)
  • We have examined the effect of IL-12-producing cellular vaccines on the cytotoxicity and proliferative potential of CD45+ tumour-infiltrating cells (TIL) in mice carrying syngeneic, HPV 16-associated tumours after chemotherapy with CBM-4A ifosfamide derivative. The chemotherapy resulted in decrease of the CD4+ and CD8+ TIL, increase of the Gr-1+/CD11b+ TIL, no changes in the infiltration with CD4+/CD25+ Treg TIL, and decrease of the cytolytic and proliferative potential of the CD45+ TIL. Subsequent immunotherapy with the IL-12-producing, genetically modified TC-1 cells increased tumour infiltration with CD8+ and CD4+ cells, decreased the Gr-1+/CD11b+ cells, and increased the cytolytic and proliferative potential of the CD45+ TIL. These findings suggest that peritumoral administration of the IL-12-producing cellular vaccine can restore the cytolytic potential and inhibit immunosuppressive TIL-dependent mechanisms.
  • We have examined the effect of IL-12-producing cellular vaccines on the cytotoxicity and proliferative potential of CD45+ tumour-infiltrating cells (TIL) in mice carrying syngeneic, HPV 16-associated tumours after chemotherapy with CBM-4A ifosfamide derivative. The chemotherapy resulted in decrease of the CD4+ and CD8+ TIL, increase of the Gr-1+/CD11b+ TIL, no changes in the infiltration with CD4+/CD25+ Treg TIL, and decrease of the cytolytic and proliferative potential of the CD45+ TIL. Subsequent immunotherapy with the IL-12-producing, genetically modified TC-1 cells increased tumour infiltration with CD8+ and CD4+ cells, decreased the Gr-1+/CD11b+ cells, and increased the cytolytic and proliferative potential of the CD45+ TIL. These findings suggest that peritumoral administration of the IL-12-producing cellular vaccine can restore the cytolytic potential and inhibit immunosuppressive TIL-dependent mechanisms. (en)
Title
  • HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy
  • HPV 16-asociované nádory: IL-12 může obnovit cytotoxické a proliferační odpovědi buněk infiltrujících nádor po chemoterapii (cs)
  • HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy (en)
skos:prefLabel
  • HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy
  • HPV 16-asociované nádory: IL-12 může obnovit cytotoxické a proliferační odpovědi buněk infiltrujících nádor po chemoterapii (cs)
  • HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy (en)
skos:notation
  • RIV/68378050:_____/09:00318305!RIV09-AV0-68378050
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • P(GA301/06/0774), Z(AV0Z50520514)
http://linked.open...iv/cisloPeriodika
  • 1
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 317911
http://linked.open...ai/riv/idVysledku
  • RIV/68378050:_____/09:00318305
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • HPV 16; vaccines; tumour-infiltrating cells (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • GR - Řecká republika
http://linked.open...ontrolniKodProRIV
  • [6A23F8131B6A]
http://linked.open...i/riv/nazevZdroje
  • International Journal of Oncology
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...vavai/riv/projekt
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 34
http://linked.open...iv/tvurceVysledku
  • Reiniš, Milan
  • Bieblová, Jana
  • Bubeník, Jan
  • Indrová, Marie
  • Pajtasz-Piasecka, E.
  • Rossowska, J.
  • Kuropka, P.
http://linked.open...ain/vavai/riv/wos
  • 000262127000017
http://linked.open...n/vavai/riv/zamer
issn
  • 1019-6439
number of pages
is http://linked.open...avai/riv/vysledek of
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 117 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software